IL1B and breast carcinoma: Interestingly, we found that tumour-derived IL1β decreased the ability of breast cancer cells to invade HUVEC cells (E0771, 0 = 0.0101; Py8119, p = 0.0231), which is opposite to the pro-metastatic effects observed toward the bone metastatic niche.